Acute heart failure with accompanying chronic obstructive pulmonary disease

Ege, Meltem Refıker; Güray, Ümit; Güray, Yeşım; Yilmaz, Mehmet Birhan; Yücel, Oğuzhan; Zorlu, Ali; Tandoğan, İzzet

doi:10.1007/s00059-012-3641-x

Cited by 3 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additionally, patients with existing CVD and newly diagnosed COPD have a higher mortality rate with BB discontinuation . However, these patients, especially those with severe COPD, remain less likely to receive a BB or may be prescribed lower doses of BBs than those without COPD …”

Section: Bbs In Copdmentioning

confidence: 99%

“…5,10 However, these patients, especially those with severe COPD, remain less likely to receive a BB or may be prescribed lower doses of BBs than those without COPD. 6,7,30 Prospective studies reviewing BB effects on respiratory function have been small, short in duration, and narrow in focus. Most have concentrated on defining the differences among the established BBs in HF-the cardioselective agents bisoprolol and metoprolol and the noncardioselective, a-blocking agent carvedilol.…”

Section: Bbs In Copdmentioning

confidence: 99%

See 1 more Smart Citation

β‐Blockers and Chronic Obstructive Pulmonary Disease: Inappropriate Avoidance?

Minor

Meyer

Long

et al. 2013

J of Clinical Hypertension

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the United States and is often accompanied by one or more comorbid conditions. While there are established morbidity and mortality benefits of β‐blocker (BB) use for certain cardiovascular conditions, data suggest that clinicians are often reluctant to prescribe them in the presence of COPD because of concerns for bronchoconstriction, despite evidence that they are typically well‐tolerated among these patients. Treatment guidelines for COPD are consistent with those for cardiovascular disease management and support the role of BBs in management of particular cardiovascular conditions, even in the presence of severe COPD. Adherence to these guidelines could result in significant decreases in morbidity and mortality among patients with COPD. Additionally, current treatments for COPD are often linked to increased cardiovascular disease events. Further study is needed to clarify and guide therapeutic management in patients with COPD.

show abstract

Section: Bbs In Copdmentioning

confidence: 99%

Section: Bbs In Copdmentioning

confidence: 99%

β‐Blockers and Chronic Obstructive Pulmonary Disease: Inappropriate Avoidance?

Minor

Meyer

Long

et al. 2013

J of Clinical Hypertension

View full text Add to dashboard Cite

show abstract

“…Por esta razón, en la EPOC han sido subutilizados debido al temor de broncoconstricción y efectos adversos, sobre todo en las personas mayores. Los pacientes con enfermedad pulmonar obstructiva crónica corresponden a edades mayores, y tienen más comorbilidades así como menor uso de beta-bloqueadores en comparación con aquellos sin ésta (17,35).…”

Section: Beta-bloqueadores Y Enfermedad Pulmonar Obstructiva Crónicaunclassified

Uso de beta-bloqueadores en pacientes con enfermedad pulmonar obstructiva crónica

Osorio

2013

rev. colomb. neumol.

View full text Add to dashboard Cite

Uso de beta-bloqueadores en pacientes con enfermedad pulmonar obstructiva crónicaUse of beta-blockers in patients with COPD RESUMEN La enfermedad pulmonar obstructiva crónica (EPOC) es un síndrome sistémico con múltiples fenotipos, en el que la enfermedad cardiovascular contribuye significativamente a la morbilidad y la mortalidad por su causa. El tabaquismo, la clase socioeconómica baja y un estilo de vida sedentario contribuyen a la historia natural de cada una de estas condiciones. La mayoría de las enfermedades cardiovasculares requieren tratamiento con beta-bloqueadores, que tradicionalmente se han contraindicado en los pacientes con EPOC; sin embargo el uso de estos fármacos se asocia a beneficios y mejores resultados en pacientes con enfermedades cardiovasculares, hipertensión, insuficiencia cardiaca, enfermedad coronaria y enfermedad pulmonar obstructiva crónica.Palabras clave: receptores adrenérgicos, beta-bloqueadores, enfermedad pulmonar obstructiva crónica, falla cardiaca. ABSTRACTChronic obstructive pulmonary disease (COPD) is a systemic syndrome with multiple phenotypes. Cardiovascular disease contributes significantly to the morbidity and mortality of COPD. Tobacco use, low socioeconomic class, and sedentary lifestyle contribute to the natural history of each of these conditions. Most cardiovascular diseases require treatment with beta-blockers. Traditionally, beta-blockers have been contraindicated in patients with COPD. However, the use of these drugs is associated with benefits and better results in patients with cardiovascular diseases, hypertension, heart failure, coronary disease, and COPD.

show abstract